Objective: Major depressive disorder (MDD) is common and associated with impaired functioning after traumatic brain injury (TBI). Few placebo-controlled antidepressant trials exist in this population. We evaluated the efficacy and tolerability of sertraline for MDD within 1 year of sustaining a TBI. Setting: Level I trauma center. Participants: Adults with MDD within 1 year of hospitalization for complicated mild to severe TBI. Design: Randomized, double-blind, placebo-controlled trial. Main Measures: Twelve-week treatment response on the 17-item Hamilton Depression Rating Scale. We also assessed symptom improvement and remission. Results: We randomized 62 participants: 32% sustained a severe TBI, 68% had significant anxiety, 63% had a history of prior MDD, and 69% had a history of alcohol or drug dependence. Depression significantly improved from baseline to 12 weeks in both treatment groups (P < .001). There were no significant differences between the sertraline and placebo groups over 12 weeks on depression severity, response, or remission. The sertraline group had significant improvement on speed of information processing compared with the placebo group (P < .006). Conclusion: Sertraline monotherapy was not superior to placebo for MDD in people with post-acute complicated mild to severe TBI. Research is needed on the effectiveness of interventions that also address the significant psychosocial needs of this population.
MDD.
1 MDD is significantly associated with comorbid anxiety 2 and substance abuse 1 and decreased quality of life. 1, 3 Despite the high rate of MDD and associated adverse outcomes during this post-acute period, less than half of those with MDD receive any medication or psychotherapeutic treatment of their depression. 1 Few randomized controlled trials have examined the efficacy of antidepressants for MDD following TBI despite the frequent use of these medications in this population. 4 Systematic reviews of depression treatment studies reveal only 1 evidence class I 5 and 1 evidence class II 6 pharmacotherapy study. [7] [8] [9] [10] On the basis of this preliminary data on efficacy and tolerability, the strongest evidence supports the use of selective serotonin reuptake inhibitors, particularly sertraline and citalopram.
Two preliminary studies by Fann et al 11 and TurnerStokes et al 12 provided evidence for the potential efficacy and tolerability of sertraline in persons with TBI and MDD. Findings from our group's initial pilot study suggested that sertraline was not only well-tolerated and potentially efficacious for treating MDD in persons with mild TBI but also associated with improvements in anger and aggression, functional status, postconcussive symptoms, and domains of subjective and objective cognitive functioning.
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In the only published evidence class I pharmacotherapy study, Ashman and colleagues 5 randomized 52 patients with mild, moderate, or severe TBI to the sertraline or placebo group (41 patients completed the study). The mean time since injury was 17.7 (SD = 13.7) years, making it difficult to ascertain the relative contribution of the TBI to their depressive episode. Although there were no statistically significant group differences in response rates or decrease in Hamilton Depression Rating Scale (HAM-D) scores over 10 weeks, among the completers, 59% of patients in the sertraline group were responders (≥50% decrease in baseline HAM-D score) whereas 32% of patients in the placebo group responded. The authors did not report final dosage ranges or specifics about adverse effects, although they report that only 1 subject withdrew because of adverse effects.
The aims of the current trial were to (1) compare the efficacy of sertraline and placebo for MDD during the first year following complicated mild to severe TBI, (2) determine tolerability of treatment with sertraline compared with placebo, and (3) evaluate secondary outcomes, including quality of life, disability, speed of information processing, postconcussive symptoms, pain, anger and aggression, and anxiety.
METHODS
Procedures and participants
Eligibility criteria for the study are described elsewhere 1 and included admission to Harborview Medical Center (a level I trauma center in Seattle, Washington) with TBI and radiologic evidence of acute, traumatically induced brain abnormality or the Glasgow Coma Scale score lower than 13 (based on the lowest score within 24 hours after admission or the first after paralytic agents were withdrawn). Participants were at least 18 years old and English speaking. We obtained a waiver of consent to determine eligibility; otherwise, participation required written consent. Study procedures were approved by the University of Washington institutional review board and followed guidelines from the Health Insurance Portability and Accountability Act.
During the surveillance phase of the study, cases with probable MDD were identified using a structured interview based on the Patient Health Questionnaire 9-item depression scale (PHQ-9), which has excellent interrater reliability (0.99) and diagnostic sensitivity (0.93) and specificity (0.89) in individuals with TBI. 14, 15 At screening, history of prior psychiatric disorders and involvement in litigation were assessed.
Subjects with probable MDD on the PHQ-9 were asked to undergo an in-person diagnostic interview using the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) (SCID). 16 To be included, patients had to meet criteria for MDD on the SCID and score at least 15 on the HAM-D, 17-item version. 17 We excluded those who met SCID criteria for bipolar disorder, a psychotic disorder, or bereavement, as well as those with suicide intent or plan. We also excluded people who had a prior adverse reaction or nonresponse to sertraline, had an unstable medical condition that would preclude treatment with sertraline, anticipated major surgery within the next 3 months, were already taking an antidepressant, or were pregnant or not using reliable birth control if a woman of childbearing age.
Randomization, which was conducted by the study biostatisticians (N.T., J.B.), following baseline assessment, was 1:1 to sertraline or placebo and stratified by a history of MDD and a history of alcohol or other substance dependence based on the SCID using permuted blocks of 2. Participants who consented to randomization were asked to refrain from engaging in non-studyrelated pharmacotherapy or psychotherapy for depression during the course of the study.
Materials
Demographic, medical, radiologic, and ICD-9 (International Classification of Diseases, Ninth Revision), diagnostic data were obtained via participant interviews, medical record reviews, and the Harborview Trauma Registry. The SCID was used to diagnose the presence of a current anxiety disorder. Race was obtained via self-report and record review. Other system injury severity was based on the Injury Severity Score excluding head injury. 18 Serum blood alcohol level and toxicology screening results (cocaine and amphetamine) were collected when available.
Study assessments and dosage titrations occurred in person at baseline and 1, 3, 6, 8, 10, and 12 weeks. The primary depression outcome was the HAM-D, 17-item version. 17 As a secondary outcome, we also included the 6-item Maier subscale of the HAM-D 19 because it is a unidimensional scale that excludes somatic items and therefore may have superior sensitivity to change in individuals with medical comorbidity. [20] [21] [22] We used a structured version of the HAM-D 23 for improved interrater reliability. All research staff conducting screening, intervention, and outcome procedures were blinded to randomization status.
Other secondary depression outcomes, assessed at each visit, were self-rated depression severity on the Symptom Checklist-20 (SCL-20) 24 and the clinicianrated Clinical Global Impression scale. 25 At baseline and 12 weeks, we also assessed quality of life (Medical Outcome Study Short-Form 36 ), 26 subjective functional impairment (Sheehan Disability Scale), 334 JOURNAL OF HEAD TRAUMA REHABILITATION/SEPTEMBER-OCTOBER 2017 of postconcussive symptom rated from 0 to 5 (Head Injury Symptom Checklist), 29 anger and aggression (Brief Anger and Aggression Questionnaire), 30 pain intensity (Brief Pain Inventory), 31 and anxiety (Hamilton Anxiety Rating Scale).
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Medication titration and tolerability
Study medication (identical-appearing sertraline or inert placebo) was administered per a flexible-dose algorithm. Medication was started at 25 mg every morning. After 1 week, the dose was adjusted up to 50 mg per day, depending on tolerability. Further adjustment was made in week 3 up to 100 mg per day and up to 150 mg per day during week 6, as tolerated. At weeks 8 and 10, the dose was adjusted up to 200 mg per day, depending on clinical response on HAM-D and tolerability. Staff counted pills at each in-person visit to monitor adherence to study drug. Tolerability, defined as new or worsening side effects, was assessed at each follow-up using a standard side effect assessment that captured the onset, severity (none, mild, moderate, and severe), and resolution of 25 medication-related symptoms.
Statistical analysis
Exact logistic regression was used to compare treatment groups on rates of response (primary outcome) and remission. Mixed-effects linear regression models were used to compare treatment efficacy of sertraline with placebo. 33 Analyses included observations at baseline and 1, 3, 6, 8, 10, and 12 weeks analyzed according to the intent-to-treat principle. Random effects were included for participants' intercepts. Fixed effects were time (linear), treatment (sertraline vs placebo), interaction of time with treatment, stratification factors, and potential confounders. The indicator of treatment effect was the interaction of time by treatment. Secondary outcomes were assessed using a similar strategy. Variables examined as potential confounders included stratification variables, age and sex, time since injury (≤3 months vs >3 months), medical comorbidity, history of depression, and current anxiety disorder. All analyses were adjusted for multiple comparisons where appropriate using the Holm-Bonferroni method. 34 All analyses were performed using SAS (version 9.3).
RESULTS
We identified 408 participants who met screening criteria, 234 completed baseline assessments (common reasons for exclusion were being bipolar, n = 15; already being on an antidepressant, n = 13; and not wanting to take an antidepressant, n = 12), and 62 participants were randomized (see Figure 1 ). Of those, 21 (68%) participants assigned to the sertraline group completed the medication protocol compared with 28 (90%) in the placebo group (P = .059). Characteristics of the study sample are presented in Tables 1 and 2 . The mean age of participants in the study was 37.5 (SD = 12.5) years (range, 18.9-66.6). Fifty (81%) were non-Hispanic white, 20 (32%) had a severe TBI, and 36 (67%) reported unstable employment status at the time of randomization. The mean time from TBI to randomization was 4.6 (SD = 2.8) months (range, 1.1-10.9). Thirty-eight (63%) reported a history of preinjury depression, 43 (69%) reported a history of alcohol or drug dependence, and 42 (68%) had a current anxiety disorder.
Treatment efficacy
The HAM-D, 17-item version, and Maier subscale scores over time are shown in Figure 2 . Within both treatment groups, HAM-D, 17-item version, Maier subscale, and SCL-20 depression scores improved from baseline to 12 weeks (all Ps < .001). However, intent-totreat adjusted models revealed no significant differences between the sertraline and placebo groups in the percentage of responders or remitters or improvement on the HAM-D, 17-item version, Maier subscale, SCL-20, or clinician ratings on the Clinical Global Impression scale from baseline to 12 weeks (see Table 3 ). Restricting analyses to participants who completed the 12-week assessment, remained on medications throughout the study, or achieved 100 mg of study drug did not alter the results (data not shown).
Participants in the sertraline group had significantly better performance on the Trail Making Test B, a measure of information processing speed, improving from 92.3 (SD = 56.5) seconds at baseline to 76.3 (SD = 55.0) seconds at 12 weeks, compared with the placebo group, which worsened from 83.0 (SD = 38.6) seconds at baseline to 97.9 (SD = 52.3) seconds at 12 weeks (P < .006) ( Table 4 ). There were no other significant group differences on secondary outcomes. When comparing the treatment responders (≥50% drop in HAM-D, 17-item version, from baseline) from both treatment groups (n = 22) with all nonresponders from both groups, responders had significantly improved mental health on the SF-36 (P = .004), anger and aggression (P < .001), and anxiety (P = .005).
Adherence and tolerability
Final study medication doses are presented in Table 5 . Only 55% of participants in the sertraline group reached at least 100 mg per day of study medication compared with 74% in the placebo group. Participants in the sertraline group took the study drug for nearly 2 weeks less than those in the placebo group.
Reported adverse effects are presented in Table 6 . There were no significant group differences in the mean number of new or worsened adverse effects. The only new or worsened adverse effects 10% or more prevalent in the sertraline group compared with the placebo group were flatulence/gas, agitation/restlessness, and decreased libido/sexual interest. Irritability was 13% more common in the placebo group than in the sertraline group. There were no serious adverse events.
DISCUSSION
To our knowledge, this is the largest randomized placebo-controlled trial of antidepressant treatment of major depression after TBI and only the second evidence class I antidepressant study in this population. Although participants in both treatment groups had significant pre-/postintervention improvement in depression severity, we did not find a significant difference in efficacy on HAM-D between sertraline and placebo over 12 weeks. Moreover, no differences were found on secondary outcomes of depression (Maier subscale, SCL-20 self-report), anxiety, postconcussive symptoms, pain, functioning, or health-related quality of life. Participants in the sertraline group showed improvement on a measure of information processing speed compared with those in the placebo group. Although not statistically significant, detailed tolerability data showed that more participants in the sertraline group reported medication adverse effects and dropped out of treatment and fewer achieved a therapeutic medication dose and duration before completing the study.
The lack of significant difference in efficacy between sertraline and placebo is consistent with the findings by Ashman and colleagues, 5 the only other evidence class I study of pharmacotherapy for depression following TBI. 7 Ashman and colleagues also found no significant depression treatment differences between sertraline and placebo. However, compared with the current study, the study by Ashman and colleagues had a higher HAM-D response rate for the sertraline group (30% vs 59%) and a lower placebo response rate (43% vs 32%). The response rate for sertraline in the current study is 37% using the criteria given in the study by Ashman and colleagues. The study by Ashman and colleagues enrolled 52 TBI patients (41 completed the study, 36% had mild TBI) an average of 17.7 (SD = 13.7) years postinjury.
In contrast, the current study enrolled 62 TBI patients with complicated mild to severe TBI (53 completed the study) within 1 year of injury who had high rates of recurrent or chronic depression, current anxiety, and a history of substance dependence. The study by Ashman and colleagues did not report detailed dosage and adverse effects data, so it is difficult to compare medication tolerability across the studies. Several possibilities exist for the lack of difference in efficacy between sertraline and placebo. First, more side effects and lower adherence to sertraline than to placebo may have contributed to the low response to sertraline. However, restricting the analyses to those who completed the intervention or achieved 100 mg per day or more did not change the results. Second, response to placebo was high and may have been boosted by frequent in-person contact and support from the study staff, particularly in patients who are often socially isolated following TBI. 35 Previous antidepressant trials have shown placebo response rates similar to those found in this study and higher antidepressant-placebo differences with greater baseline depression severity. 36 Although we did require a minimum baseline HAM-D score of 15, a higher cutoff may have resulted in different findings. Third, our study sample exhibited high rates of psychiatric comorbidity, including current anxiety and a history of depression and substance dependence, which can contribute to depression treatment resistance. 37 Fourth, there is evidence that the HAM-D may have suboptimal psychometric properties (eg, responsiveness to change) in persons with TBI. 38 Finally, the significant psychosocial challenges, exemplified by the large proportion of patients in our study with unstable employment, unmarried, and on Medicaid, faced by depressed individuals in the year following TBI have been well-documented. 35 Antidepressants alone are unlikely to adequately treat MDD for many of these individuals.
Antidepressants have been shown to improve depression-related cognitive impairment. 39, 40 Our finding that sertraline, perhaps due to its strong dopaminergic activity, 41 was associated with significantly better performance on a measure of information processing speed compared with placebo is consistent with prior findings in persons with TBI and depression. 13, 42 Although antidepressant administration in patients with (42) 13 (45) Mixed-effects models adjusted for time, stratification, age, and current anxiety. Reported means and response and remission models use last observation carried forward if there is no 12-week value. Response, remission, and CGI exact logistic regression models adjust only for stratification due to insufficient sample size. c One subject in each of the sertraline and placebo groups dropped out after baseline assessment and were not included in the response and remission models.
TBI without depression has not been shown to improve cognitive functioning, 43 the use of antidepressants to improve cognitive function in patients with TBI and comorbid depression warrants further study.
The 22 study participants whose depression responded to treatment intervention also had significant improvement in anxiety, anger and aggression, and mental health-related quality of life, compared with those who did not respond to treatment, after correcting for multiple comparisons. This finding suggests that decreasing depression is associated with improvement in other common comorbid psychiatric conditions, although the directionality of these improvements cannot be determined from these data. Several study limitations warrant mention. The sample size was limited to 62 participants from a single site. Despite the high rate of MDD in our study population, 1 only a small proportion of participants were eligible and consented to this highly controlled efficacy study. Participants had limited sociodemographic diversity and high depression chronicity and psychiatric comorbidity, which may limit generalizability of findings to other TBI populations. We did not enroll persons with uncomplicated mild TBI, a group that also experiences high rates of MDD. 44 There was a differentially higher rate of study drug discontinuation in the sertraline group, which may have biased the results. Prior nonresponse to antidepressants and the high chronicity of depression may have negatively influenced response rates. Finally, as noted earlier, the choice of the HAM-D as the primary outcome measure in this TBI population may have biased the results toward the null.
Despite these limitations, our findings have relevance for clinical practice. It is important to educate TBI patients about the potential adverse effects of antidepressants and closely monitor adherence since many of the adverse effects (eg, gastrointestinal, psychiatric) may be treatable. It is possible that patients with TBI may be less able to tolerate medication adverse effects than other patient groups, particularly during the first year after injury. Our prior research documented that patients with TBI often have strong depression treatment preferences, which should be considered before embarking on a specific treatment approach. 45 Our results are suggestive of potential beneficial effects of sertraline on cognition in the post-acute phase for patients with MDD, an area that deserves further study. Furthermore, multimodal treatment approaches, such as those that include cognitive behavioral strategies, 46, 47 that address psychosocial stressors may be needed to maximize depression treatment effectiveness.
Given the high prevalence of depression following TBI, strategies to decrease the burden of depression in this population are needed. Studies that administered sertraline to prevent depression following TBI show promise for decreasing early onset of depression while taking the antidepressant. 48, 49 However, from a population-based standpoint, more research is needed to determine whether administration of prophylactic antidepressant is a cost-effective strategy for the prevention of depression and its associated sequelae.
Future pharmacotherapy studies using other medications and with larger sample sizes are needed to determine which patient, injury, clinical, pharmacologic, and biomarker variables may predict treatment response. Because of the many potential biological, psychological, and social contributors to depression following TBI, we need studies of combined pharmacotherapy and psychotherapy, as well as patient-centered, collaborative, stepped care treatment approaches that also address comorbid conditions. To maximize generalizability, more "effectiveness" trials in real-world settings are needed, including those that test innovative delivery systems such as telehealth models that have the potential of overcoming treatment barriers faced by patients with TBI. 46, 50 
